OTC
33.08USD
0.00 (0.00%)
We have scored 4 news catalysts on Zealand Pharma A/S (ZLDPF) over the past 12 months. The biggest single-day move next to one of them came Jun 9, 2026, when ZLDPF closed +7.9%: “Why Eli Lilly Stock Climbed to a New All-Time High Today”. Coverage across the window leans positive (average ticker sentiment +0.15). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.4B
P/E
—
EPS
—
Beta
0.60
52W range
33.08-83.12
Day range
33.08–34.50
Open
34.50
Prev close
33.08
Volume
100
Avg volume
541
Dividend
0.00
IPO
2013-02-25
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Zealand Pharma A/S — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ZLDPF: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Based in Copenhagen, Denmark, Zealand Pharma A/S operates as a biotechnology company dedicated to the entire lifecycle of peptide-based medicines – from their initial discovery and development through to their ultimate commercialization. Its therapeutic portfolio primarily targets gastrointestinal and metabolic disorders, alongside other specialized conditions where existing treatments are insufficient. Currently, Zealand Pharma offers lixisenatide, marketed as Adlyxin and Lyxumia. They also commercialize Dasiglucagon, available in a single-use syringe or autoinjector format, which addresses severe hypoglycemia, congenital hyperinsulinism, and hypoglycemia following bariatric surgery. Additionally, Dasiglucagon is part of a dual-hormone artificial pancreas system designed for automated diabetes management. Beyond its current offerings, the company maintains a robust development pipeline. Notably, Dasiglucagon is advancing through Phase III clinical trials specifically for congenital hyperinsulinism, building on its existing applications. Another key pipeline candidate is glepaglutide, a long-acting GLP-2 analog, also in Phase III trials for the management of short bowel syndrome. Zealand Pharma A/S has established strategic collaboration agreements with several prominent pharmaceutical and biotech partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc. Established in 1998, the company maintains its headquarters in Copenhagen, Denmark.
